Vanguard Total International Stock ETF
Latest Vanguard Total International Stock ETF News and Updates
Novartis Focuses on Portfolio Prioritization to Boost Profitability
To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.
Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017
Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.
Bill Gross: Possibility of Deglobalization in the Economy
Gross warned about deglobalization in the global economy. Trade between nations, exacerbating immigration issues, and stagnant economic growth formed his belief.
A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance
In 3Q16, Valeant Pharmaceuticals (VRX) generated revenues of $2.4 billion, compared with $2.2 billion in 3Q17.
How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?
In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.
How Novartis Is Aiming to Increase Entresto Sales in 2017
In 2017, Novartis (NVS) expects its heart failure drug, Entresto, to earn revenues in excess of $500 million.
AstraZeneca’s Tagrisso Had a Strong Commercial Launch in 2016
After its commercial launch in 41 countries, AstraZeneca’s Tagrisso has witnessed a solid uptake, earning revenues of $276.0 million in 2016 YTD.